Clinical Trial

Testing Treatment for HIV

Study Description

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - PGT121 + VRC07-523LS

PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously

Biological - PGT121 + VRC07-523LS + PGDM1400

PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously

Additional Information

Official Study Title

A Phase 1/2a Open Label Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

Clinical Trial ID

NCT03721510

ParticipAid ID

azpn8d